Drugs that contain Atogepant
1. Drug name - QULIPTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9499545 | ABBVIE INC | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(9 years from now) | |
| US8754096 | ABBVIE INC | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(9 years from now) | |
| US9850246 | ABBVIE INC | Process for making CGRP receptor antagonists |
Mar, 2033
(10 years from now) | |
| CN103328478A | ABBVIE INC | Piperidones Carboxamide Indane Cgrp Receptor Antagonist |
Nov, 2031
(9 years from now) | |
| CN103328478B | ABBVIE INC | Piperidone Carboxamide Nitrogen Mixed Indene Into Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| IN201303390P4 | ABBVIE INC | Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| IN289826B | ABBVIE INC | Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| EP2821407B1 | ABBVIE INC | Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| EP2638042A1 | ABBVIE INC | Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| EP2821407A1 | ABBVIE INC | Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| EP2638042B1 | ABBVIE INC | Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| EP2849568B1 | ABBVIE INC | Process For Making Cgrp Receptor Antagonists |
Mar, 2033
(10 years from now) | |
| EP2849568A4 | ABBVIE INC | Process For Making Cgrp Receptor Antagonists |
Mar, 2033
(10 years from now) | |
| EP2849568A1 | ABBVIE INC | Process For Making Cgrp Receptor Antagonists |
Mar, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10117836 | ABBVIE INC | Tablet formulation for CGRP active compounds |
Jan, 2035
(12 years from now) | |
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 10MG | TABLET;ORAL | Prescription |
| 30MG | TABLET;ORAL | Prescription |
| 60MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.